学术 Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer 179 Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer:A multicenter study 183 Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarioa After Treatments With Sequential ALK Inhibitors:A Brief Report 188 Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations 192 Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer 194 Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression 196 国际指南的肺癌表皮生长因子受体基因突变和间变 淋巴瘤激酶基因重排检测及其临床进展 198 Long?term Survival Associated with Crizotinib in a Lung Cancer Patient with a Pulmonary Artery Embolism 200 c?ROS癌基因1融合阳肺腺癌54例临床特征分析 202 Detection of non-reciprocal/reciprocal ALK translocation as poor predictive marker in first-line crizotinib-treated ALK-rearranged non-small cell lung cancer patients 204 Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib:a case report 206 Investigation on the survival implications of PD-L1 expression status in ALK-rearranged advanced non-small cell lung cancer treated with first-line crizotinib 208 Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer 210 Loss of 5' ALK leads to better response to crizotinib in sarcomas with ALK rearrangement 212